Merck Cozaar Nephropathy Label Should Include Cardioprotection Uncertainty
Merck's Cozaar labeling for type 2 diabetic nephropathy should convey questions about cardioprotective effect and caution about substitution for ACE inhibitors, FDA's Cardiovascular & Renal Drugs Advisory Committee suggested at its April 12 meeting
You may also be interested in...
CDER’s Bob Temple explains how competitors could actually help speed up a drug approval but also hold a product to a higher standard.
An analysis of recent drug approvals that took longer than one year shows no indications of a more conservative attitude by FDA, Office of Medical Policy Director Robert Temple, MD, told the Food & Drug Law Institute conference April 17 in Washington, D.C
An advisory committee recommendation for Merck's Cozaar in the treatment of nephropathy in type 2 diabetes patients reflects supportive evidence from Bristol-Myers Squibb/Sanofi's Avapro data.